Alzheimer's-plagued Colombia region is focus of drug trial

December 17, 2012 by Chris Kraul, Los Angeles Times

The unusually high incidence of early-onset Alzheimer's disease in this isolated cattle town has thrust it to the forefront of global efforts to find a cure for the debilitating malady.

Next spring, 100 residents of this region in northwestern Colombia who are known to carry a mutant gene linked to the disease will begin taking a produced by the U.S. biotechnology firm Genentech. The five-year clinical trial, called the Alzheimer's Prevention Initiative, will cost $100 million. The effort is backed by the U.S. National Institutes of Health and includes UCLA.

What sets this drug trial apart is that the patients, most of them in their 30s, will begin treatment long before they show symptoms of Alzheimer's. Researchers hope the drug will prevent its onset by blocking or slowing the formation of amyloid plaques in the brain that are associated with the devastating illness.

Because of a rare among interrelated families, scores of residents here and in surrounding towns are getting Alzheimer's by their late 40s, about 15 years ahead of the norm. The cases can be traced to a "": a 's "misspelled" gene, passed down over generations, that makes developing Alzheimer's a virtual certainty.

"It's a heavy burden for the relatives when the victims have to stop working and raising their children at such an early age," said Carlos Orrego, administrator at San Juan de Dios Hospital, Yarumal's biggest. "For the families, the burden can last a very long time."

But the tragic circumstances also make this community an ideal place to test the Genentech drug, called crenezumab, which attacks beta amyloids and prevents them from becoming toxic.

Dr. Francisco Lopera, a co-manager of the trial and a neurologist at the University of Antioquia medical school in Medellin, 80 miles south of here, said it's the first test of its kind to be carried out on apparently healthy people. Lopera confirmed the genetic link to Alzheimer's cases here in the 1980s.

"Anti-amyloid drugs have been used before, but they have failed because they have been taken by patients already suffering from dementia - in other words, too late," Lopera said. "We are optimistic. We aren't sure it will prevent the disease, but it could delay it for many years, and that's important."

A hundred carriers of the mutant gene will take the drug over five years, and 100 carriers will take a placebo, as will 100 at-risk people who do not have the .

A "branch study" also will be conducted at UCLA's Geffen School of Medicine, where researchers have discovered a similar genetic disposition among members of an extended family from Jalisco state in Mexico. As many as 30 who have immigrated to Southern California could take part, neurology professor Dr. John Ringman said.

"It's an exciting and wise investment by the U.S. government in the cutting edge of Alzheimer's research," Ringman said. UCLA is looking for more at-risk patients to participate.

As many as 150 other U.S. patients who are Alzheimer's "mutation carriers" will take part in the trial at a dozen sites, said Dr. Eric Reiman of the Banner Alzheimer's Institute in Phoenix and a co-leader of the project. The inclusion of American patients is important so that Colombians don't feel exploited, he said.

"We think it's important to share benefits and risks with families in the United States," Reiman said.

The Alzheimer's Prevention Initiative is the "cornerstone of the U.S. government's national plan to attack Alzheimer's disease," he said.

The high-stakes research project reflects the growing health threat that Alzheimer's represents. An estimated 5.4 million Americans suffer from the disease, including 1 in 8 Americans older than 65. The percentage will grow in coming years as the population ages.

The cost of treatment and caregiving for Alzheimer's patients is soaring past $200 billion a year, according to the Alzheimer's Association, providing ample incentive for the government to help find a cure.

To track the drug's progress in inhibiting plaques, patients will receive intravenous injections of a lightly radioactive imaging agent that will bind to amyloids floating in the fluid surrounding the brain. Patients will then undergo periodic brain scans to see whether the are forming.

Genentech, which spent five years developing crenezumab, is shouldering $65 million of the study's $100 million cost. The NIH and the Banner Alzheimer's Institute are financing the balance.

Richard Scheller, an executive vice president of Genentech, said crenezumab has proved effective in blocking Alzheimer's-like symptoms in laboratory mice.

The trial could also prove or disprove the hypothesis of many researchers that amyloids are at the root of Alzheimer's, which is still a mystery.

" are the target," UCLA's Ringman said. "A guaranteed slam-dunk target? No. But it's the best we've got."

Said Scheller: "I've been a scientist a long time and sometimes complicated experiments don't work. But based on encouraging results so far, I'm cautiously optimistic we can help these folks."

Explore further: Trial set to see if drug can prevent Alzheimer's

Related Stories

Trial set to see if drug can prevent Alzheimer's

May 16, 2012
(HealthDay) -- Researchers are preparing to test an experimental drug in people genetically primed to develop Alzheimer's disease.

Researchers find earliest known signs of Alzheimer's in people with genetic mutation that causes inherited form

November 5, 2012
Researchers have found the earliest signs of Alzheimer's disease yet detected in a group of people with a rare, inherited form of the disease, according to two Articles published in The Lancet Neurology. The findings raise ...

Alzheimer’s prevention better than a cure

July 14, 2011
In a new study published in Nature, Dr. Sam Gandy from Mount Sinai Medical Center argues that finding a cure for Alzheimer’s disease may be near impossible and that the best hope for researchers is to focus on prevention, ...

Novel approaches to treating Alzheimer's disease include early intervention

May 16, 2012
(Medical Xpress) -- Researchers at the Comprehensive Alzheimer’s Program at the University of California, San Diego School of Medicine have announced two new clinical trials for patients with either mild to moderate ...

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Recommended for you

Anxiety: An early indicator of Alzheimer's disease?

January 12, 2018
A new study suggests an association between elevated amyloid beta levels and the worsening of anxiety symptoms. The findings support the hypothesis that neuropsychiatric symptoms could represent the early manifestation of ...

One of the most promising drugs for Alzheimer's disease fails in clinical trials

January 11, 2018
To the roughly 400 clinical trials that have tested some experimental treatment for Alzheimer's disease and come up short, we can now add three more.

Different disease types associated with distinct amyloid-beta prion strains found in Alzheimer's patients

January 9, 2018
An international team of researchers has found different disease type associations with distinct amyloid-beta prion strains in the brains of dead Alzheimer's patients. In their paper published in Proceedings of the National ...

Advances in brain imaging settle debate over spread of key protein in Alzheimer's

January 5, 2018
Recent advances in brain imaging have enabled scientists to show for the first time that a key protein which causes nerve cell death spreads throughout the brain in Alzheimer's disease - and hence that blocking its spread ...

Molecular mechanism behind HIV-associated dementia revealed

January 5, 2018
For the first time, scientists have identified and inhibited a molecular process that can lead to neurodegeneration in patients with HIV, according to a Northwestern Medicine study published in Nature Communications.

Mice with frequent flier miles advance the Alzheimer's cause

January 4, 2018
Alzheimer's disease wreaks emotional havoc on patients, who are robbed of their memories, their dignity, and their lives. It's financially devastating as well: care for Alzheimer's patients is predicted to top $1 trillion ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.